US FDA accepts Vanda Pharmaceuticals’ BLA for imsidolimab to treat Generalized Pustular Psoriasis: Washington Friday, February 27, 2026, 17:00 Hrs [IST] Vanda Pharmaceuticals In ...
If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results